Quaternary lactam compound and pharmaceutical use thereof

1. A compound of formula (I), a solvate, mixtures thereof, and pharmaceutically acceptable salts thereof,

wherein, R 1 is selected from halogen, C 1-10 alkyl, —(CH 2 ) t NR 6 R 7 , —COR 5a , —COOR 5b , —C(O) m (CH 2 ) t NR 6 R 7 , —(CH 2 ) t NHC(O) m C 1-10 alkyl, —NHC(O) m (CH 2 ) n C(O) m C 1-6 alkyl, —S(O) m (CH 2 ) t NR 6 R 7 , —NH(CH 2 )S(O) m R 5a , —NH(CH 2 ) t S(O) m —OR 5b , —OR 5b , —SR 5b , —(CH 2 ) t CN, and —O(CH 2 ) n NR 6 R 7 ;

R 2 is selected from the group consisting of hydrogen, halogen, hydroxyl, C 1-10 alkyl, C 1-10 alkoxy, —(CH 2 ) t X(CH 2 ) n NR 6 R 7 , —(CH 2 ) t CN, —(CH 2 ) t COR 5a , —(CH 2 ) t COOR 5b , —(CH 2 ) t NR 6 R 7 , —C(O) m (CH 2 ) t NR 6 R 7 , —CONHS(O) m R 5a , and —CONHS(O) m —OR 5b ;

X is O or S;

A is heteroaryl;

B is selected from benzopyrrolidinyl, benzopiperidinyl, benzopiperazinyl, and triazolopiperazinyl, and the fused bicyclic group in B is optionally further substituted with 1 to 3 R 4b ;

R 4b is the same or different and are independently selected from hydrogen, oxo, halogen, —(CH 2 ) t CN, C 1-10 alkyl, C 1-10 alkoxy, halogenated C 1-10 alkyl, halogenated C 1-10 alkoxy, C 3-10 cycloalkyl, C 3-10 cycloalkyloxy, aryl, amino, nitro, —(CH 2 ) t NR 6 R 7 , —(CH 2 ) t NHC(O) m C 1-10 alkyl, —(CH 2 ) t CONR 6 R 7 , —(CH 2 ) t COR 5a , —(CH 2 ) t COOR 5b , —SR 5b , and —OR 5b ; and R 4b is optionally substituted with one or more of the following groups: hydrogen, ═O, halogen, C 1-10 alkyl, C 1-10 alkoxy, and aryl;

in the above groups, each R 5a is the same or different and is independently selected from hydrogen, halogen, C 1-10 alkyl, halogenated C 1-10 alkyl, and aryl;

in the above groups, R 5b , R 6 , and R 7 are the same or different and are independently selected from hydrogen, C 1-10 alkyl, halogenated C 1-10 alkyl, C 3-10 cycloalkyl, heterocyclyl, aryl, and heteroaryl;

in the above groups, each n is the same or different and is independently selected from integers from 1 to 10;

in the above groups, each m is the same or different and is independently 1 or 2; and

in the above groups, each t is the same or different and is independently selected from integers from 0 to 10.

2. The compound of claim 1 , wherein R 1 is selected from halogen, C 1-10 alkyl, C 1-10 alkoxy, —(CH 2 ) t NR 6 R 7 , —COR 5a , —COOR 5b , —C(O)(CH 2 ) t NR 6 R 7 , —(CH 2 ) t NHC(O) m C 1-10 alkyl, —NHC(O) m (CH 2 ) n C(O) m C 1-6 alkyl, —S(O) m (CH 2 ) t NR 6 R 7 , —NH(CH 2 ) t S(O) m R 5a , —SR 5b , —(CH 2 ) t CN, and —O(CH 2 ) n NR 6 R 7 .

3. The compound of claim 1 , wherein the compound has the following structure:

4. A compound selected from

5. A preparation method of the compound of formula (I) of claim 1 , comprising the following steps:

1) reacting compound (e) with triphosgene or sulfur dichloride under alkaline condition to obtain compound (f); and

2) reacting compound (f) with compound (A 0 ) under alkaline condition to obtain compound (I).

6. A pharmaceutical composition, comprising at least one selected from the compound of formula (I), the solvate, mixtures thereof, and pharmaceutically acceptable salts thereof of claim 1 , and an optional pharmaceutically acceptable carrier and/or excipient.

7. A pharmaceutical preparation, comprising the pharmaceutical composition of claim 6 , wherein the pharmaceutical preparation includes tablet, pill, granule, capsule, injection, suspension, drop, extract, ointment, patch, emulsion, film, suppository, paste, gel, or spray.

8. A combined preparation, comprising combining the pharmaceutical composition of claim 6 with at least one of other anticoagulant drugs, antithrombotic drugs or antivenous thromboembolic drugs; wherein the anticoagulant drugs, antithrombotic drugs or antivenous thromboembolic drugs are selected from heparin, low molecular weight heparin LMWH, enoxaparin, warfarin, rivaroxaban, apixaban, edoxaban, betrixaban, omisaraban, aspirin, ticlopidine, clopidogrel, tirofiban, coumarin, urokinase, and platelet protein IIb/IIIa receptor antagonist.

9. A method of treating disorders related to thrombosis or thromboembolism, comprising administering an effective amount of the pharmaceutical composition of claim 6 to a subject in need thereof, wherein the disorders related to thrombosis or thromboembolism are selected from arterial cardiovascular thromboembolic disorders, venous cardiovascular thromboembolic disorders, thromboembolic disorders in the cardiac chamber or peripheral circulation, unstable angina, acute coronary syndrome, atrial fibrillation, myocardial infarction, transient ischemic attack, stroke, atherosclerosis, peripheral occlusive arterial disease, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, coronary arterial thrombosis, cerebral arterial thrombosis, cerebral embolism, renal embolism, pulmonary embolism, and thrombosis due to medical implants, devices, or processes in which blood is exposed to artificial surfaces that promote thrombosis.

10. The compound of claim 1 , wherein B is

and is optionally substituted with 1 to 3 R 4b .

11. The compound of claim 1 , wherein A is heteroaryl.

12. The compound of claim 1 , wherein R 2 is selected from —(CH 2 ) t X(CH 2 ) n NR 6 R 7 , —(CH 2 ) t CN, —(CH 2 ) t NR 6 R 7 , —(CH 2 ) t COR 5a , —(CH 2 ) t COOR 5b , —C(O) m (CH 2 ) t NR 6 R 7 , and —CONHS(O) m R 5a .

13. The compound of claim 1 , wherein each R 5a is the same or different and is independently selected from hydrogen, halogen, C 1-4 alkyl, halogenated C 1-4 alkyl, and aryl.

14. The compound of claim 1 , wherein R 5b , R 6 , and R 7 are the same or different and are independently selected from hydrogen, C 1-4 alkyl, halogenated C 1-4 alkyl, and aryl.